Source comparison
BPC-157 Tennis Elbow Mechanism: Comparison to Standard Treatments
NSAIDs (ibuprofen, naproxen) COX enzyme inhibition reduces prostaglandin-mediated inflammation 7–14 days None. Pain relief only, no structural repair BPC-157 upregulates growth factor receptors to drive angiogenesis and collagen synthesis rather than suppressi
This comparison does not assign a generated winner or score.
- NSAIDs (ibuprofen, naproxen)
- COX enzyme inhibition reduces prostaglandin-mediated inflammation
- 7–14 days
- None. Pain relief only, no structural repair
- BPC-157 upregulates growth factor receptors to drive angiogenesis and collagen synthesis rather than suppressing inflammatory mediators
- Cortisone injection
- Glucocorticoid receptor activation suppresses cytokine release and immune cell migration
- Single injection, relief lasts 6–12 weeks
- Negative. Repeated cortisone weakens tendon collagen long-term
- BPC-157 promotes collagen deposition and cross-linking rather than immune suppression, avoiding the structural weakening effect cortisone causes
- Eccentric exercise protocol
- Mechanical loading stimulates fibroblast activity and collagen remodeling through mechanotransduction
- 12 weeks minimum (3x/week)
- Positive. Improves collagen alignment and tensile strength when performed correctly
- BPC-157 accelerates the same fibroblast-mediated collagen remodeling pathway, potentially shortening the eccentric training timeline required for full recovery
- Platelet-rich plasma (PRP)
- Autologous growth factors (PDGF, TGF-β, VEGF) delivered via centrifuged platelet concentrate
- 1–3 injections over 8–12 weeks
- Positive. Enhances collagen synthesis and angiogenesis through endogenous growth factors
- BPC-157 and PRP share overlapping mechanisms (both upregulate VEGF and PDGF pathways), but BPC-157 offers more consistent dosing control and doesn't require blood draw/centrifugation